Media headlines about Arca Biopharma (NASDAQ:ABIO) have trended somewhat positive this week, according to AlphaOne Sentiment. AlphaOne, a division of Accern, scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arca Biopharma earned a media sentiment score of 0.05 on AlphaOne’s scale. AlphaOne also assigned media stories about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have impacted AlphaOne Sentiment’s analysis:
- Arca Biopharma Inc (ABIO) Releases Quarterly Earnings Results (americanbankingnews.com)
- ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Results of Operations and Financial Condition (4-traders.com)
- BRIEF-ARCA Biopharma Q1 loss per share $0.48 (reuters.com)
- ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update (finance.yahoo.com)
Arca Biopharma (NASDAQ:ABIO) remained flat at $2.40 during midday trading on Friday. 1,162 shares of the company’s stock traded hands. Arca Biopharma has a 12-month low of $2.15 and a 12-month high of $3.93. The firm’s market cap is $21.91 million. The stock has a 50 day moving average price of $2.46 and a 200 day moving average price of $2.50.
Arca Biopharma (NASDAQ:ABIO) last issued its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter. On average, analysts expect that Arca Biopharma will post ($1.75) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Arca Biopharma (ABIO) Getting Somewhat Favorable Media Coverage, Report Shows” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/05/19/arca-biopharma-abio-given-daily-news-impact-rating-of-0-05-updated.html.
In other news, Director Daniel J. Mitchell acquired 11,000 shares of the company’s stock in a transaction dated Tuesday, May 2nd. The stock was acquired at an average cost of $2.71 per share, for a total transaction of $29,810.00. Following the acquisition, the director now directly owns 11,000 shares in the company, valued at approximately $29,810. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert E. Conway acquired 25,000 shares of the company’s stock in a transaction dated Friday, March 24th. The shares were purchased at an average price of $2.59 per share, with a total value of $64,750.00. Following the completion of the acquisition, the director now owns 25,000 shares in the company, valued at $64,750. The disclosure for this purchase can be found here. Insiders sold a total of 3,870 shares of company stock valued at $9,628 over the last quarter. 2.46% of the stock is currently owned by insiders.
Arca Biopharma Company Profile
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
Receive News & Ratings for Arca Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.